Evidence map›Paper›PMID 30041665›Full record

ArticleJournal of experimental & clinical cancer research : CR2018

Ajuba inhibits hepatocellular carcinoma cell growth via targeting of β-catenin and YAP signaling and is regulated by E3 ligase Hakai through neddylation.

Min Liu, Ke Jiang, Guibin Lin, Peng Liu, Yumei Yan, Tian Ye, Gang Yao, Martin P Barr, Dapeng Liang, Yang Wang and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Unveiling the dynamics and therapeutic potential of mInternational journal of biological sciences · 2025
    Review
  10. Review
  11. Protein neddylation and its role in health and diseases.Signal transduction and targeted therapy · 2024
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Diagnostic, Therapeutic, and Prognostic Value of the mFrontiers in cell and developmental biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Min LiuInstitute of Cancer Stem Cell, Dalian Medical University Cancer Center, 9 Lvshun Road South, Dalian, 116044, China.
Ke JiangInstitute of Cancer Stem Cell, Dalian Medical University Cancer Center, 9 Lvshun Road South, Dalian, 116044, China.
Guibin LinHuizhou No. 3 People's Hospital, Affiliated Hospital of Guangzhou Medical University, No. 1 Xuebei Street, Qiaodong Road, Huizhou, 615000, China.
Peng LiuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital, Dalian Medical University, No. 222 Zhongshan Road, Dalian, 116021, China.
Yumei YanThe First Department of Ultrasound, The First Affiliated Hospital, Dalian Medical University, No. 222 Zhongshan Road, Dalian, 116021, China.
Tian YeInstitute of Cancer Stem Cell, Dalian Medical University Cancer Center, 9 Lvshun Road South, Dalian, 116044, China.
Gang YaoInstitute of Cancer Stem Cell, Dalian Medical University Cancer Center, 9 Lvshun Road South, Dalian, 116044, China.
Martin P BarrThoracic Oncology Research Group, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St. James's Hospital & Trinity College, Dublin, Ireland.
Dapeng LiangInstitute of Cancer Stem Cell, Dalian Medical University Cancer Center, 9 Lvshun Road South, Dalian, 116044, China.
Yang WangInstitute of Cancer Stem Cell, Dalian Medical University Cancer Center, 9 Lvshun Road South, Dalian, 116044, China.
Peng GongDepartment of general surgery, Shenzhen University General Hospital, No. 1098 Xueyuan Road, Shenzhen, 518055, China. gongpengdalian@163.com.
Songshu MengInstitute of Cancer Stem Cell, Dalian Medical University Cancer Center, 9 Lvshun Road South, Dalian, 116044, China. ssmeng@dmu.edu.cn.
Haozhe PiaoDepartment of neurosurgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No. 44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, China. piaohaozhe@cancerhosp-ln-cmu.com.
Dalian Medical University · CNChina Medical University · CNFirst Affiliated Hospital of Dalian Medical University · CNHuizhou Central People's Hospital · CNShenzhen University · CNSt. James's Hospital · IE

Funding

Clinical Capability Construction Project for Liaoning Provincial Hospitals LNCCC-B04-2015Guiding funds for the development of local science and technology by the central government 2017106014National Natural Science Foundation of China 81402071National Natural Science Foundation of China 81473504National Natural Science Foundation of China 81572707National Natural Science Foundation of China 81772973
6 · The paper itself

Abstract

backgroundAberrant activation of β-catenin and Yes-associated protein (YAP) signaling pathways has been associated with hepatocellular carcinoma (HCC) progression. The LIM domain protein Ajuba regulates β-catenin and YAP signaling and is implicated in tumorigenesis. However, roles and mechanism of Ajuba expression in HCC cells remain unclear. The E3 ligase Hakai has been shown to interact with other Ajuba family members and whether Hakai interacts and regulates Ajuba is unknown.

methodsHCC cell lines stably depleted of Ajuba or Hakai were established using lentiviruses expressing shRNAs against Ajuba or Hakai. The effects of Ajuba on HCC cells were determined by a number of cell-based analyses including anchorage-independent growth, three dimension cultures and trans-well invasion assay. In vivo tumor growth was determined in a xenograft model and Ajuba expression in tumor sections was examined by immunohistochemistry. Co-immunoprecipitation, confocal microscopy and immunoblot assay were used to examine the expression and interaction between Ajuba and Hakai.

resultsDepletion of Ajuba in HCC cells significantly enhanced anchorage-independent growth, invasion, the formation of spheroids and tumor growth in a xenograft model, suggesting a tumor suppressor function for Ajuba in HCC. Mechanistically, Ajuba depletion triggered E-cadherin loss and β-catenin translocation with increased Cyclin D1 levels. In addition, depletion of Ajuba upregulated the levels of YAP and its target gene CYR61. Furthermore, siRNA-mediated knockdown of either β-catenin or YAP attenuated the pro-tumor effects by Ajuba depletion on HCC cells. Notably, Ajuba stability in HCC cells was regulated by Hakai, an E3 ligase for E-cadherin. Hakai interacted with Ajuba via its HYB domain and induced Ajuba neddylation, which was antagonized by the neddylation inhibitor, MLN4924, but not MG132. We further show that overexpression of Hakai in HCC cells markedly increased anchorage-independent growth, spheroid-formation ability and tumor growth in xenografts whereas Hakai depletion resulted in these opposite effects, indicating an oncogenic role for Hakai in HCC. Hakai also induced β-catenin translocation with increased levels of Cyclin D1.

conclusionsOur data suggest a role for Ajuba and Hakai in HCC, and uncover the mechanism underlying the regulation of Ajuba stability.

Indexed as

Animalsbeta CateninCarcinoma, HepatocellularCell Line, TumorHumansLIM Domain ProteinsLiver NeoplasmsMiceMice, NudeTransfectionUbiquitin-Protein LigasesAJUBA protein, humanbeta CateninLIM Domain ProteinsUbiquitin-Protein LigasesAjubaHakaiHepatocellular carcinomaNeddylationYAPβ-Catenin

Identifiers

PMID30041665
PMCPMC6057013
OpenAlexW2884030111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.